RACHELLE DOODY to Biomarkers
This is a "connection" page, showing publications RACHELLE DOODY has written about Biomarkers.
Connection Strength
0.600
-
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23; 370(4):311-21.
Score: 0.059
-
A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25; 369(4):341-50.
Score: 0.057
-
Molecular neuropsychology: creation of test-specific blood biomarker algorithms. Dement Geriatr Cogn Disord. 2014; 37(1-2):45-57.
Score: 0.055
-
Differences in the association of peripheral insulin and cognitive function in non-diabetic Alzheimer's disease cases and normal controls. J Alzheimers Dis. 2013; 34(2):449-56.
Score: 0.055
-
A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol. 2010 Sep; 67(9):1077-81.
Score: 0.047
-
Evolving early (pre-dementia) Alzheimer's disease trials: suit the outcomes to the population and study design. J Nutr Health Aging. 2010 Apr; 14(4):299-302.
Score: 0.045
-
Development of a quantitative semi-mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q-ATN model). Alzheimers Dement. 2023 06; 19(6):2287-2297.
Score: 0.027
-
Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD): A Report of an International Research Collaboration Network. J Alzheimers Dis. 2022; 85(1):31-45.
Score: 0.026
-
Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report. J Prev Alzheimers Dis. 2022; 9(2):231-235.
Score: 0.026
-
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nat Med. 2021 Jul; 27(7):1187-1196.
Score: 0.025
-
Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force. J Prev Alzheimers Dis. 2021; 8(3):306-312.
Score: 0.024
-
The Future of Anti-Amyloid Trials. J Prev Alzheimers Dis. 2020; 7(3):146-151.
Score: 0.022
-
Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report. J Prev Alzheimers Dis. 2019; 6(3):169-173.
Score: 0.021
-
Statistical Model of Dynamic Markers of the Alzheimer's Pathological Cascade. J Gerontol B Psychol Sci Soc Sci. 2018 08 14; 73(6):964-973.
Score: 0.020
-
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul; 9(4):438-44.
Score: 0.014
-
A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. PLoS One. 2011; 6(12):e28092.
Score: 0.013
-
A blood-based algorithm for the detection of Alzheimer's disease. Dement Geriatr Cogn Disord. 2011; 32(1):55-62.
Score: 0.012
-
Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J Alzheimers Dis. 2011; 27(2):259-69.
Score: 0.012
-
Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2011 Jan 18; 76(3):280-6.
Score: 0.012
-
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009 Dec 15; 73(24):2061-70.
Score: 0.011
-
Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology. 2007 Oct 16; 69(16):1622-34.
Score: 0.010
-
Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003 Dec; 60(12):1696-702.
Score: 0.007